MTN
microbicide trials network

HOPE
HIV Open-label Prevention Extension
Out of ASPIRE, there is HOPE

Looking Forward to HOPE…

MTN Regional Meeting

Monday October 5th

Cape Town, South Africa

HOPE

HIV Open-label Prevention Extension

Out of ASPIRE, there is HOPE

15 min	**Timeline and Operational Considerations** Nyaradzo Mgodi, HOPE Protocol Co-chair Ashley Mayo, FHI 360
15 min	**Community Engagement for OLEs** MU-JHU CRS, Kampala, Uganda
15 min	**Adherence and Accountability** Kalendri Naidoo, CAPRISA eThekwini CRS, Durban, South Africa
15 min	**Q&A/Group Discussion**

Out of ASPIRE, there is HOPE

HOPE
HIV Open-label Prevention Extension
Out of ASPIRE, there is HOPE

Large Scale Implementation

ASPIRE
A Study to Prevent Infection with a Ring for Extended Use

From Research to Rollout



Adapted from: *AVAC Report 2013: Research & Reality*

Open Label Extensions (OLEs)

- Ethical obligation to provide access to proven products in the immediate post-trial period to former participants
- Not full out delivery = has to incorporate being a regulated piece of research
- Partial step towards understanding what ring use would be like in a population with full access and knowledge about it's then-proven effectiveness

HOPE
HIV Open-label Prevention Extension
Out of ASPIRE, there is HOPE

OLEs are not the same as the trial

- Primary goal → provide **first access** to safe and effective product to participants who took part in ASPIRE
- OLEs are not to be confused with demonstration projects or full-scale product introduction *but they should move the field in that direction*
- But they are also not a continuation of the active arm of an RCT

HOPE
HIV Open-label Prevention Extension
Out of ASPIRE, there is HOPE

Three examples

Trial results		Open label use
Partners PrEP Study		Partners PrEP Study Extension
iPrEx		iPrEx OLE
CAPRISA 004		CAPRISA 008

HOPE
HIV Open-label Prevention Extension
Out of ASPIRE, there is HOPE

MTN
microbicide trials network

Open Label Extensions

	Enrollment	Timeline to Implementation	Results
Partners PrEP Study Extension	89% of those eligible	3 months after results	High adherence and continued HIV protection
iPrEx OLE	65% of those eligible (of whom ~75% accepted PrEP [PrEP use was optional])	7 months after results	High adherence to open-label PrEP and high HIV protection with high adherence
CAPRISA 008	85% of those eligible	Protocol finalized 4 months after results; 2 year gap due to regulatory delays.	Pending

MTN-025 Design: Protocol v2.0



- Nonrandomized, open-label, phase IIIB trial, transitioning from a monthly to a quarterly visit schedule

HOPE
HIV Open-label Prevention Extension
Out of ASPIRE, there is HOPE

MTN
microbicide trials network

Key scientific outcomes

- Important data on safety with open-label use, coincident with regulatory submission of this product
- Assessment of adherence, transitioning from monthly clinical trial visits to quarterly visits to mimic delivery settings
- Measurement of the key outcomes of HIV-1 incidence and resistance once efficacy is known
- Understanding declines of the ring (as one prevention tool is not for everyone)

HOPE Implementation Timeline



Regulatory Approvals

- Priority: Timeliness in resubmission to IRBs
  - Recommend starting ICF translations now, to be able to submit quickly once ASPIRE results are released
  - GOAL: have supplemental materials that require IRB approval available at the same time as ICF resubmission
  - Be familiar with your IRB meeting dates/submission deadlines for Q1 2016

HOPE Provisional Approvals

Site	Primary IRB	Other IRB(s)	Drug Regulatory
MRC CTU	Received	N/A	Submitted
eThekwini	Received		
Cape Town	Received		
Wits RHI	Received		
Zimbabwe CTU	Submitted	Submitted	Pending Submission
Lilongwe	Submitted	Pending Submission	Pending Submission
Blantyre	Submitted	Pending Submission	Pending Submission
Uganda	Submitted	Pending Submission	Pending Submission

From Phase III to OLE

- What questions should we be asking now?
  - How do we best engage and educate communities about OLEs?
  - How to pace and manage accrual of an already identified study population?
  - What will our approach be to adherence support?
  - Are there concerns about product accountability and how do we manage these?
  - How to best retain participants on a quarterly schedule?
  - Others???

Thank you

MTN microbicide trials network

ASPIRE A Study to Prevent Infection with a Ring for Extended Use

National Institutes of Health

Statistical Center for HIV/AIDS Research & Prevention SCHARP

fhi360

Malawi College of Medicine – JHU Research Project

WRHI

HOPE HIV Open-label Prevention Extension
Out of ASPIRE, there is HOPE

MRC SOUTH AFRICA

CAPRISA CENTRE FOR THE AIDS PROGRAMME OF RESEARCH IN SOUTH AFRICA

UNC PROJECT Lilongwe, Malawi

INTERNATIONAL PARTNERSHIP FOR MICROBICIDES

DESMOND TUTU HIV FOUNDATION

University of Zimbabwe, School of Medicine

Participants and communities

Acknowledgements

The Microbicide Trials Network is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with co-funding from the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.